SCHEMBL4726211

SCHEMBL4726211

CCCCC(=O)[N][C@H](C(=O)O)C(C)C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 1/20 0.38
CES1 P23141 1/20 0.38
PLA2G2A P14555 1/20 0.37
PLA2G5 P39877 1/20 0.37
DDAH1 O94760 1/20 0.36
ALDH1A1 P00352 3/20 0.35
AKR1B1 P15121 1/20 0.35
TP53 P04637 1/20 0.35
CA2 P00918 1/20 0.35
MAPK1 P28482 1/20 0.35
ACE2 Q9BYF1 1/20 0.35
PPARG P37231 6/20 0.34
PPARD Q03181 6/20 0.34
PPARA Q07869 6/20 0.34
HDAC11 Q96DB2 5/20 0.34
TSHR P16473 4/20 0.34
GPR84 Q9NQS5 4/20 0.34
TLR2 O60603 2/20 0.34
TDP1 Q9NUW8 2/20 0.34
FABP4 P15090 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8135244 1.00 CES2 (0.38) CES2CES1PLA2G2APLA2G5DDAH1
SCHEMBL7312353 0.77 CES1 (0.46) CES2CES1ALDH1A1AKR1B1TP53
SCHEMBL4679170 0.74 CES1 (0.42) CES2CES1DDAH1ALDH1A1AKR1B1
SCHEMBL7309900 0.71 CES2 (0.48) CES2CES1ALDH1A1AKR1B1MAPK1
SCHEMBL8393264 0.69 CES2 (0.50) CES2CES1ALDH1A1MAPK1PPARG
SCHEMBL4521252 0.68 CES2 (0.44) CES2CES1ALDH1A1AKR1B1MAPK1
SCHEMBL6970922 0.67 CES1 (0.44) CES2CES1ALDH1A1AKR1B1TP53
SCHEMBL840697 0.67
SCHEMBL543757 0.67 CES1 (0.55) CES2CES1ALDH1A1AKR1B1TP53
SCHEMBL9560717 0.66 CES1 (0.48) CES2CES1ALDH1A1AKR1B1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7385062-B2 Process for the preparation of phenyltetrazole derivatives DIPHARMA S.P.A. (IT) 2008-06-10 US claimed
WO-2008012852-A1 INTERMEDIATE COMPOUNDS FOR THE PREPARATION OF ANGIOTENSIN II ANTAGONISTS S.I.M.S. S.r.l. - SOCIETÀ ITALIANA MEDICINALI SCANDICCI (IT) 2008-01-31 WO claimed
EP-1660463-B1 A PROCESS FOR THE PREPARATION OF PHENYLTETRAZOLE DERIVATIVES DIPHARMA FRANCIS SRL (IT) 2007-12-05 EP claimed
US-20070093540-A1 PROCESS FOR THE PREPARATION OF ANGIOTENSIN II ANTAGONISTIC COMPOUNDS DIPHARMA S.P.A. (IT) 2007-04-26 US claimed
EP-1777224-A2 A process for the preparation of angiotensin II antagonistic compounds Dipharma S.p.A. (IT) 2007-04-25 EP claimed
JP-2007501770-A 2007-02-01 JP claimed
US-20060183916-A1 Process for the preparation of phenyltetrazole derivatives DIPHARMA S.P.A. (IT) 2006-08-17 US claimed
EP-1660463-A1 A PROCESS FOR THE PREPARATION OF PHENYLTETRAZOLE DERIVATIVES Dipharma S.p.A. (IT) 2006-05-31 EP claimed
WO-2005014560-A1 A PROCESS FOR THE PREPARATION OF PHENYLTETRAZOLE DERIVATIVES DIPHARMA S.P.A. (IT) 2005-02-17 WO claimed
US-7385062-B2 Process for the preparation of phenyltetrazole derivatives DIPHARMA S.P.A. (IT) 2008-06-10 US disclosed
WO-2008012852-A1 INTERMEDIATE COMPOUNDS FOR THE PREPARATION OF ANGIOTENSIN II ANTAGONISTS S.I.M.S. S.r.l. - SOCIETÀ ITALIANA MEDICINALI SCANDICCI (IT) 2008-01-31 WO disclosed
EP-1660463-B1 A PROCESS FOR THE PREPARATION OF PHENYLTETRAZOLE DERIVATIVES DIPHARMA FRANCIS SRL (IT) 2007-12-05 EP disclosed
US-20070093540-A1 PROCESS FOR THE PREPARATION OF ANGIOTENSIN II ANTAGONISTIC COMPOUNDS DIPHARMA S.P.A. (IT) 2007-04-26 US disclosed
EP-1777224-A2 A process for the preparation of angiotensin II antagonistic compounds Dipharma S.p.A. (IT) 2007-04-25 EP disclosed
EP-1660463-A1 A PROCESS FOR THE PREPARATION OF PHENYLTETRAZOLE DERIVATIVES Dipharma S.p.A. (IT) 2006-05-31 EP disclosed
WO-2005014560-A1 A PROCESS FOR THE PREPARATION OF PHENYLTETRAZOLE DERIVATIVES DIPHARMA S.P.A. (IT) 2005-02-17 WO disclosed
EP-0994881-B1 ORTHO-METALATION PROCESS FOR THE SYNTHESIS OF 2-SUBSTITUTED-1-(TETRAZOL-5-YL)BENZENES ZAMBON SPA (IT) 2002-09-18 EP disclosed
US-6271375-B1 ESPECIALLY PREPARATION OF TASOSARTAN; GRIGNARD REAGENTS ZAMBON GROUP S.P.A. (IT) 2001-08-07 US disclosed
EP-0994881-A1 ORTHO-METALATION PROCESS FOR THE SYNTHESIS OF 2-SUBSTITUTED-1-(TETRAZOL-5-YL)BENZENES ZAMBON GROUP S.p.A. (IT) 2000-04-26 EP disclosed
WO-1999001459-A1 ORTHO-METALATION PROCESS FOR THE SYNTHESIS OF 2-SUBSTITUTED-1-(TETRAZOL-5-YL)BENZENES ZAMBON GROUP S.P.A. (IT) 1999-01-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070093540-A1 PROCESS FOR THE PREPARATION OF ANGIOTENSIN II ANTAGONISTIC COMPOUNDS AGTR2, AGTR1, ACE2 CES2 2201/4885CES1 2437/4885PLA2G2A 1985/4885
US-20060183916-A1 Process for the preparation of phenyltetrazole derivatives AGTR2, ACE, AGTR1 CES2 2978/4885CES1 3467/4885PLA2G2A 4550/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.